Compare Hut 8 Corp (HUT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Mesoblast Limited — how do they compare? Hut 8 Corp trades at $79.32 (market cap $9.82B), while Mesoblast Limited trades at $14.1 (market cap $1.75B). The key difference: Hut 8 Corp is far larger — about 5.6× Mesoblast Limited's market cap, and Hut 8 Corp is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Mesoblast Limited for 14 Days on average.
| HUT | MESO | |
|---|---|---|
Market Cap | $9.82B | $1.75B |
Volume | 10,272,678 | 239,027 |
Sector | Financials | Health |
52-Week High | $133.02 | $20.96 |
52-Week Low | $33.76 | $13.19 |
Typical Hold Time | 11 Days | 14 Days |
Enterprise Value | $17.25B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $89.3, down 3.17% today, amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 with a negative net margin, though revenue grew to $235.12 million. Recent news highlights a $1.07 billion credit facility and AI infrastructure deals, fueling optimism. Analyst consensus is strongly bullish with a $156.79 price target.
The outlook balances strong analyst support and AI infrastructure growth potential against persistent losses and high valuation multiples. Key risks include execution on profitability and competitive pressures in the digital infrastructure space.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
